

Ruben Pio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5665280/publications.pdf>

Version: 2024-02-01

129
papers

6,471
citations

53794

45
h-index

76900

74
g-index

133
all docs

133
docs citations

133
times ranked

9407
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. <i>Cancer Letters</i> , 2022, 529, 70-84.	7.2	51
2	Two cell line models to study multiorgan metastasis and immunotherapy in lung squamous cell carcinoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	2.4	5
3	Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. <i>Cancer Discovery</i> , 2022, 12, 1356-1377.	9.4	22
4	Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	7.1	5
5	Surgical Outcomes in a Lung Cancer-Screening Program Using Low Dose Computed Tomography. <i>Archivos De Bronconeumologia</i> , 2021, 57, 101-106.	0.8	9
6	Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death. <i>Cancer Discovery</i> , 2021, 11, 1268-1285.	9.4	42
7	Molecular biomarkers in early stage lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1165-1185.	2.8	23
8	SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. , 2021, 9, e001496.		42
9	Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1327-1337.	2.8	3
10	The Complement System in Ovarian Cancer: An Underexplored Old Path. <i>Cancers</i> , 2021, 13, 3806.	3.7	5
11	A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer. <i>Translational Research</i> , 2021, 233, 77-91.	5.0	15
12	Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge. <i>Frontiers in Immunology</i> , 2021, 12, 767376.	4.8	10
13	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. <i>Nature Cancer</i> , 2020, 1, 75-85.	13.2	68
14	DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies CREBBP as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC). <i>Cancers</i> , 2020, 12, 1824.	3.7	6
15	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. <i>Cancers</i> , 2020, 12, 3169.	3.7	10
16	Editorial: The Role of Complement in Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 139.	4.8	2
17	Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors. <i>Annals of Oncology</i> , 2020, 31, 274-282.	1.2	36
18	Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. <i>Scientific Reports</i> , 2019, 9, 15400.	3.3	13

#	ARTICLE	IF	CITATIONS
19	“Stealth” corporate innovation: an emerging threat for therapeutic drug development. <i>Nature Immunology</i> , 2019, 20, 1409-1413.	14.5	7
20	YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 888-899.	5.6	50
21	Complementing the Cancer-Immunity Cycle. <i>Frontiers in Immunology</i> , 2019, 10, 774.	4.8	136
22	Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. <i>Cancer Letters</i> , 2019, 453, 21-33.	7.2	22
23	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. <i>International Journal of Cancer</i> , 2019, 145, 1991-2001.	5.1	32
24	Complement in Metastasis: A Comp in the Camp. <i>Frontiers in Immunology</i> , 2019, 10, 669.	4.8	23
25	TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 2134.	2.4	17
26	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. <i>Thorax</i> , 2019, 74, 371-379.	5.6	9
27	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. <i>Journal of Thoracic Oncology</i> , 2019, 14, 343-357.	1.1	306
28	Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment. <i>Seminars in Cell and Developmental Biology</i> , 2019, 85, 153-163.	5.0	89
29	Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1164-1176.	5.6	77
30	Complement C4d-specific antibodies for the diagnosis of lung cancer. <i>Oncotarget</i> , 2018, 9, 6346-6355.	1.8	39
31	Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm. <i>BMC Genomics</i> , 2018, 19, 703.	2.8	20
32	The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2018, 98, 1562-1574.	3.7	30
33	The sVEGFR1-i13 splice variant regulates a β 1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1596-1608.	6.4	18
34	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. <i>Cancer Medicine</i> , 2018, 7, 3474-3483.	2.8	11
35	A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients. <i>Journal of Pathology</i> , 2018, 245, 421-432.	4.5	29
36	Abstract LB-084: Dasatinib reduces tumor growth in xenograft models derived from human lung tumors with YES1 overexpression. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
37	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	7.7	80
38	MA17.10 YES1 Kinase is a New Therapeutic Target in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S446-S447.	1.1	1
39	A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. <i>Cancer Discovery</i> , 2017, 7, 694-703.	9.4	160
40	Telomere length, COPD and emphysema as risk factors for lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1601521.	6.7	19
41	Assessment of EGF receptor ligand expression in gastric carcinoma and in lesional skin of paraneoplastic acanthosis nigricans: a case report. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e301-e302.	2.4	2
42	Abstract LB-117: Dasatinib for the treatment of patients with non-small cell lung cancer harboring YES1 amplification. , 2017, , .		1
43	EventPointer: an effective identification of alternative splicing events using junction arrays. <i>BMC Genomics</i> , 2016, 17, 467.	2.8	31
44	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. <i>Tumor Biology</i> , 2016, 37, 13687-13694.	1.8	37
45	A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer. <i>Molecular Oncology</i> , 2016, 10, 1437-1449.	4.6	60
46	Innate immune mediators in cancer: between defense and resistance. <i>Immunological Reviews</i> , 2016, 274, 290-306.	6.0	104
47	A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3361-3371.	7.0	113
48	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	1.1	48
49	Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 85063-85078.	1.8	16
50	Epigenetic alterations leading to Tmprss4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients. <i>Oncotarget</i> , 2016, 7, 22752-22769.	1.8	29
51	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. <i>BMC Genomics</i> , 2015, 16, 752.	2.8	12
52	Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. <i>Oral Diseases</i> , 2015, 21, 899-904.	3.0	27
53	Expression of Sirtuin 1 and 2 Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0124670.	2.5	79
54	Improving Selection Criteria for Lung Cancer Screening. The Potential Role of Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 924-931.	5.6	90

#	ARTICLE	IF	CITATIONS
55	Cribado de Cáncer de pulmón: catorce años de experiencia del Programa Internacional de Detección Precoz de Cáncer de Pulmón con TBDR de Pamplona (P-IELCAP). Archivos De Bronconeumología, 2015, 51, 169-176.	0.8	59
56	Lung Cancer Screening: Fourteen Year Experience of the Pamplona Early Detection Program (P-IELCAP). Archivos De Bronconeumología, 2015, 51, 169-176.	0.8	28
57	Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. European Journal of Cancer, 2015, 51, 1897-1903.	2.8	10
58	Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 986-992.e11.	0.8	6
59	Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLoS ONE, 2015, 10, e0119878.	2.5	23
60	Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration. Nanomedicine, 2014, 9, 2109-2121.	3.3	23
61	TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. British Journal of Cancer, 2014, 110, 1545-1551.	6.4	21
62	New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations. International Journal of Cancer, 2014, 135, 2516-27.	5.1	14
63	Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. EMBO Molecular Medicine, 2014, 6, 539-550.	6.9	21
64	The Role of Complement in Tumor Growth. Advances in Experimental Medicine and Biology, 2014, 772, 229-262.	1.6	155
65	TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. Molecular Cancer Research, 2014, 12, 660-669.	3.4	59
66	Identification of Alternative Splicing Events Regulated by the Oncogenic Factor SRSF1 in Lung Cancer. Cancer Research, 2014, 74, 1105-1115.	0.9	77
67	Abstract 2477: Max inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. , 2014, , .		1
68	Silica-induced Chronic Inflammation Promotes Lung Carcinogenesis in the Context of an Immunosuppressive Microenvironment. Neoplasia, 2013, 15, 913-1118.	5.3	33
69	Complement inhibition in cancer therapy. Seminars in Immunology, 2013, 25, 54-64.	5.6	121
70	Phosphorylated tubulin adaptor protein CRMP2 as prognostic marker and candidate therapeutic target for NSCLC. International Journal of Cancer, 2013, 132, 1986-1995.	5.1	32
71	Multiscale in situ analysis of the role of dyskerin in lung cancer cells. Integrative Biology (United Kingdom), 2013, 5, 1313-1321.	1.3	13
72	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1385-1393.	6.3	127

#	ARTICLE	IF	CITATIONS
73	Smokers with CT Detected Emphysema and No Airway Obstruction Have Decreased Plasma Levels of EGF, IL-15, IL-8 and IL-1ra. <i>PLoS ONE</i> , 2013, 8, e60260.	2.5	9
74	Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. <i>Journal of Immunology</i> , 2012, 189, 4674-4683.	0.8	219
75	Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. <i>Journal of Clinical Oncology</i> , 2012, 30, 1129-1136.	1.6	63
76	Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. <i>Vaccine</i> , 2012, 30, 2848-2858.	3.8	21
77	Identification of Novel Deregulated RNA Metabolism-Related Genes in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e42086.	2.5	48
78	Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. <i>Clinical Cancer Research</i> , 2011, 17, 4155-4166.	7.0	47
79	Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes. <i>Oncologist</i> , 2011, 16, 877-885.	3.7	75
80	Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. <i>British Journal of Cancer</i> , 2011, 105, 1608-1614.	6.4	64
81	Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. <i>BMC Genomics</i> , 2010, 11, 352.	2.8	25
82	The Oncoprotein SF2/ASF Promotes Non-Small Cell Lung Cancer Survival by Enhancing Survivin Expression. <i>Clinical Cancer Research</i> , 2010, 16, 4113-4125.	7.0	46
83	Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2665-2672.	2.5	27
84	VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. <i>Molecular Cancer</i> , 2010, 9, 320.	19.2	55
85	TGFBI expression is associated with a better response to chemotherapy in NSCLC. <i>Molecular Cancer</i> , 2010, 9, 130.	19.2	61
86	Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. <i>Molecular Cancer</i> , 2010, 9, 139.	19.2	69
87	Alternative Splicing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 674-678.	1.1	52
88	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. <i>European Respiratory Journal</i> , 2009, 34, 1477-1486.	6.7	15
89	A gene-alteration profile of human lung cancer cell lines. <i>Human Mutation</i> , 2009, 30, 1199-1206.	2.5	113
90	Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1771-1780.	4.2	34

#	ARTICLE	IF	CITATIONS
91	Current challenges in lung cancer early detection biomarkers. <i>European Journal of Cancer</i> , 2009, 45, 377-378.	2.8	11
92	Expression of $\hat{\pm}$ CP $\hat{\epsilon}$ 4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. <i>International Journal of Cancer</i> , 2008, 122, 1512-1520.	5.1	20
93	Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. <i>BMC Molecular Biology</i> , 2008, 9, 103.	3.0	40
94	Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. <i>Human Mutation</i> , 2008, 29, 617-622.	2.5	226
95	SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays. <i>Genome Biology</i> , 2008, 9, R46.	9.6	26
96	Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. <i>Molecular Immunology</i> , 2008, 45, 169-179.	2.2	67
97	Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. <i>Histology and Histopathology</i> , 2008, 23, 33-40.	0.7	16
98	Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth. <i>Journal of Immunology</i> , 2007, 178, 5991-5998.	0.8	87
99	Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. <i>European Respiratory Journal</i> , 2007, 30, 608-610.	6.7	29
100	Alternative splicing: an emerging topic in molecular and clinical oncology. <i>Lancet Oncology</i> , The, 2007, 8, 349-357.	10.7	230
101	Molecular Analysis of a Multistep Lung Cancer Model Induced by Chronic Inflammation Reveals Epigenetic Regulation of p16, Activation of the DNA Damage Response Pathway. <i>Neoplasia</i> , 2007, 9, 840-IN12.	5.3	86
102	Adrenomedullin Is a Cross-Talk Molecule that Regulates Tumor and Mast Cell Function during Human Carcinogenesis. <i>American Journal of Pathology</i> , 2006, 168, 280-291.	3.8	74
103	Molecular Profiling of Computed Tomography Screen-Detected Lung Nodules Shows Multiple Malignant Features. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 373-380.	2.5	17
104	Adrenomedullin: An Esoteric Juggernaut of Human Cancers. , 2006, , 453-458.		2
105	Expression of Complement Factor H by Lung Cancer Cells. <i>Cancer Research</i> , 2004, 64, 6310-6318.	0.9	108
106	$\hat{\pm}$ CP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not Its Alternative Splice Variant $\hat{\pm}$ CP-4a, Is Underexpressed in Lung Cancer. <i>Cancer Research</i> , 2004, 64, 4171-4179.	0.9	27
107	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. <i>Oncogene</i> , 2004, 23, 4037-4040.	5.9	111
108	Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre-mRNA processing. <i>Molecular Carcinogenesis</i> , 2004, 41, 187-196.	2.7	63

#	ARTICLE	IF	CITATIONS
109	Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. <i>Lung Cancer</i> , 2003, 41, 131-143.	2.0	138
110	Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo. <i>Molecular and Cellular Endocrinology</i> , 2003, 199, 179-187.	3.2	19
111	Mapping of the Adrenomedullin-Binding Domains in Human Complement Factor H. <i>Hypertension Research</i> , 2003, 26, S55-S59.	2.7	19
112	The Effects of Adrenomedullin Overexpression in Breast Tumor Cells. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1226-1237.	6.3	103
113	Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma. <i>Microscopy Research and Technique</i> , 2002, 57, 23-27.	2.2	19
114	Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. <i>Microscopy Research and Technique</i> , 2002, 57, 110-119.	2.2	46
115	Cancer and diabetes: two pathological conditions in which adrenomedullin may be involved. <i>Peptides</i> , 2001, 22, 1719-1729.	2.4	10
116	Complement Factor H Is a Serum-binding Protein for Adrenomedullin, and the Resulting Complex Modulates the Bioactivities of Both Partners. <i>Journal of Biological Chemistry</i> , 2001, 276, 12292-12300.	3.4	214
117	Expression of the adrenomedullin binding protein, complement factor H, in the pancreas and its physiological impact on insulin secretion. <i>Journal of Endocrinology</i> , 2001, 170, 503-511.	2.6	27
118	Presence of immunoreactive adrenomedullin in human and bovine milk. <i>Peptides</i> , 2000, 21, 1859-1863.	2.4	28
119	Hypoxia-Inducible Factor-1 (HIF-1) Up-Regulates Adrenomedullin Expression in Human Tumor Cell Lines during Oxygen Deprivation: A Possible Promotion Mechanism of Carcinogenesis. <i>Molecular Endocrinology</i> , 2000, 14, 848-862.	3.7	221
120	Hypoxia-Inducible Factor-1 (HIF-1) Up-Regulates Adrenomedullin Expression in Human Tumor Cell Lines during Oxygen Deprivation: A Possible Promotion Mechanism of Carcinogenesis. <i>Molecular Endocrinology</i> , 2000, 14, 848-862.	3.7	72
121	Adrenomedullin Binding Protein in the Plasma of Multiple Species: Characterization by Radioligand Blotting. <i>Endocrinology</i> , 1999, 140, 4908-4911.	2.8	67
122	Underlying Disease Stress Augments Plasma and Tissue Adrenomedullin (AM) Responses to Endotoxin: Colocalized Increases in AM and Inducible Nitric Oxide Synthase within Pancreatic Islets ¹ . <i>Endocrinology</i> , 1999, 140, 5402-5411.	2.8	25
123	Is adrenomedullin a causal agent in some cases of type 2 diabetes?. <i>Peptides</i> , 1999, 20, 1471-1478.	2.4	59
124	Adrenomedullin Binding Protein in the Plasma of Multiple Species: Characterization by Radioligand Blotting. <i>Endocrinology</i> , 1999, 140, 4908-4911.	2.8	25
125	Underlying Disease Stress Augments Plasma and Tissue Adrenomedullin (AM) Responses to Endotoxin: Colocalized Increases in AM and Inducible Nitric Oxide Synthase within Pancreatic Islets. <i>Endocrinology</i> , 1999, 140, 5402-5411.	2.8	5
126	The Role of Adrenomedullin as a Growth Regulatory Peptide in the Normal and Malignant Setting. <i>Journal of Animal Science</i> , 1999, 77, 55.	0.5	15

#	ARTICLE	IF	CITATIONS
127	Granule associated DNase in T4 and T8 lymphocytes from patients with autoimmune diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1998, 1406, 51-61.	3.8	3
128	Nitric Oxide Activates Granule-Associated DNase in Human Monocytes. <i>Nitric Oxide - Biology and Chemistry</i> , 1998, 2, 165-173.	2.7	5
129	Monocyte Inducible Nitric Oxide Synthase in Multiple Sclerosis: Regulatory Role of Nitric Oxide. <i>Nitric Oxide - Biology and Chemistry</i> , 1997, 1, 95-104.	2.7	38